Chiusura precedente | 5,0000 |
Aperto | 5,0000 |
Denaro | 4,6000 |
Domanda | 5,0000 |
Prezzo d'esercizio | 10,00 |
Scadenza | 2025-01-17 |
Min-Max giorno | 5,0000 - 5,0000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 386 |
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for presentation highlight Travere’s leadership and commitment in the field of rare kidney disease SAN DIEGO, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming Ame
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 29,250 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan